Atlas Trials

Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Clinical trial NCT03962465 · UNKNOWN

Trial details

NCT number
NCT03962465
Sponsor
University of Virginia
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Acute Lymphoblastic Leukemia
Start date
2022-07-22
Primary completion
2023-07-15
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.